Resource Logo
Being Alive

MEDICAL UPDATE: Alpha Interferon in Combination With AZT And ddC




 

Being Alive 1992 Oct 5: 6

Burroughs-Wellcome, manufacturer of AZT and a form of alpha interferon, is sponsoring a 76 week study in eight cities throughout the US (the study site closest to Los Angeles is San Francisco). This study will compare the efficacy of the combination of AZT and ddC to that of the combination of AZT, ddC and alpha interferon.

The study participants will be in the 300-500 T-cell range. Researchers are looking to raise average T-cell count to the 800 range.

What makes this study a landmark is the inclusion of a drug that is not an RT inhibitor. Alpha interferon is believed to interfere in the HIV life cycle at a point different from that of AZT, ddC or ddI. This has the potential of providing a more potent combination antiviral therapy than we currently have with just the RT inhibitors. 



 




Information in this article was accurate in October 5, 1992. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.